Alembic Pharma receives USFDA approval for travopost ophthalmic solution

Alembic Pharmaceuticals has received final USFDA approval for its abbreviated new drug application (ANDA) travoprost ophthalmic solution USP, 0.004%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Travatan ophthalmic solution, 0.004%, of Alcon Pharmaceuticals (Alcon).

Travoprost ophthalmic solution USP, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.